NDA 210923 · Vancocin Italia
Mulpleta
Lusutrombopag · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 31, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
1 Phase 3, 2 recruiting
FAERS reports
39
27 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 9, 2025.
MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1 )
Mechanism: Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- MULPLETA · LUSUTROMBOPAG 3MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lusutrombopag" as an intervention, any sponsor and status, largest first.
- Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective ProcedureStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04915287 · 476 participants (planned) · Start Jun 6, 2021 · Primary completion Jun 30, 2023
Drug: Avatrombopag maleate; Platelet transfusion and 1 more · For: Thrombocytopenia; Drugs; Chronic Liver Disease
Sites: Beijing, China
- Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive ProceduresPivotal-lookingCompleted
ShionogiIndustry
NCT02389621 · 215 participants · Start Jun 15, 2015 · Primary completion Apr 5, 2017
Drug: Lusutrombopag; Placebo · For: Chronic Liver Disease; Thrombocytopenia
Anhui Provincial HospitalGovernment (non-federal)
NCT06673498 · 60 participants (planned) · Start Nov 10, 2024 · Primary completion Nov 30, 2025
Drug: Lusutrombopag combined with recombinant human thrombopoietin · For: Thrombocytopenia
Sites: Fuyang, China; Hefei, China
- Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell TransplantationRecruiting
The General Hospital of Western Theater CommandAcademic, hospital or other
NCT07483385 · 45 participants (planned) · Start Jan 13, 2026 · Primary completion Jan 28, 2027
Drug: Lusutrombopag · For: Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation; Hematologic Disorders
Sites: Chengdu, China
- A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With LusutrombopagStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT06426043 · 40 participants (planned) · Start Jun 2024 · Primary completion Jun 2025
Drug: Lusutrombopag · For: Aplastic Anemia
Sites: Beijing, China
ShionogiIndustry
NCT01054443 · 20 participants · Start Mar 18, 2010 · Primary completion Nov 24, 2010
Drug: Placebo; Lusutrombopag · For: Immune Thrombocytopenia (ITP)
Sites: Anaheim, California; Los Angeles, California; Washington D.C., District of Columbia · 19 sites in all
ShionogiIndustry
NCT01129024 · 19 participants · Start Apr 29, 2010 · Primary completion Jun 30, 2011
Drug: Lusutrombopag · For: Immune Thrombocytopenia
Sites: Anaheim, California; Los Angeles, California; Washington D.C., District of Columbia · 19 sites in all
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06287567 · 17 participants · Start Apr 17, 2024 · Primary completion Nov 13, 2024
Drug: Lusutrombopag Oral Tablet · For: Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia
Sites: Tianjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3
- drug ineffective3
- nausea3
- ascites2
- diarrhoea2
- headache2
- hospitalisation2
- mesenteric vein thrombosis2
- pain2
- pancytopenia2
- portal vein thrombosis2
- pulmonary embolism2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mulpleta (Lusutrombopag)
2024 spending
$205K
Beneficiaries
17
24 claims
Per beneficiary
$12,062
$1,171.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,020,766 |
| 2021 | $523,751 |
| 2022 | $324,612 |
| 2023 | $277,673 |
| 2024 | $205,053 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
Ding Z, Wu H, Zeng Y, et al. · Hepatol Int 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME, Bentley R, Marcella S, et al. · Adv Ther 2022 · Meta-Analysis, Systematic Review
- Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
Tsuji Y, Kawaratani H, Ishida K, et al. · Dig Dis 2020 · Clinical Trial
- Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hidaka H, Kurosaki M, Tanaka H, et al. · Clin Gastroenterol Hepatol 2019 · Clinical Trial, Phase III, Multicenter Study
- Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. · Hepatology 2019 · Clinical Trial, Phase III, Multicenter Study
- Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N, Büyükkaramikli N, Penton H, et al. · Health Technol Assess 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Vancocin Italia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.